ArticleThe American journal of pathology2000
Telomerase activity in melanocytic lesions: A potential marker of tumor biology.
Article in The American journal of pathology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 75 citations in OpenAlex.
- Telomerase Activity in Melanoma: Impact on Cancer Cell Proliferation Kinetics, Tumor Progression, and Clinical Therapeutic Strategies-A Scoping Review.Current oncology (Toronto, Ont.) · 2026Review
- TERT Immunohistochemistry in Thin Melanomas Compared to Melanocytic Nevi.Diagnostics (Basel, Switzerland) · 2025Article
- TERT Promoter Mutations and Telomerase in Melanoma.Journal of oncology · 2022Review
- Cancer-associated POT1 mutations lead to telomere elongation without induction of a DNA damage response.The EMBO journal · 2021Article
- ETS1, nucleolar and non-nucleolar TERT expression in nevus to melanoma progression.Oncotarget · 2017Article
- Review
- Telomerase promoter mutations in cancer: an emerging molecular biomarker?Virchows Archiv : an international journal of pathology · 2014Review
- The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia.Annual review of pathology · 2014Review
- MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy.Carcinogenesis · 2012Review
- Malignancy without immortality? Cellular immortalization as a possible late event in melanoma progression.Pigment cell & melanoma research · 2011Article
- Cellular senescence in naevi and immortalisation in melanoma: a role for p16?British journal of cancer · 2006Article
- Melanocytic dysplastic naevi occupy the middle ground between benign melanocytic naevi and cutaneous malignant melanomas: emerging clues.Journal of clinical pathology · 2005Review
- [Proliferation and hTERT expression in neuroblastoma].Der Pathologe · 2004Article
- Flow cytometric analysis of DNA, telomerase content and multi-gene expression in esophageal epithelial dysplasia.World journal of gastroenterology · 2003Article
- [The dysplastic nevus. Separate entity, melanoma precursor or diagnostic dilemma?].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2003Review
- Review
- Full-length telomerase reverse transcriptase messenger RNA is an independent prognostic factor in neuroblastoma.The American journal of pathology · 2003Article
- Tiptoeing to chromosome tips: facts, promises and perils of today's human telomere biology.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2002Review
- Telomere and telomerase in the initial stage of immortalization of esophageal epithelial cell.World journal of gastroenterology · 2002Article
- Regulation of telomerase activity by alternate splicing of human telomerase reverse transcriptase mRNA in a subset of neuroblastomas.The American journal of pathology · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Telomerase activation, being a cardinal requirement for immortalization, is a crucial step in the development of malignancy. With a view toward diagnostic and biological aspects in melanocytic neoplasia, we investigated the relative levels of telomerase activity in 72 nevi and 16 malignant melanomas by means of a modified telomeric repeat amplification protocol (TRAP) assay, including an internal amplification standard. We further compared telomerase activity with the expression of two different proliferation-specific proteins, Ki-67 and repp86, a protein expressed exclusively in the cell cycle phases S, G2, and M. Telomerase activity was associated with the overall growth fraction (Ki-67) but showed a closer correlation with the expression of repp86. Both telomerase activity and proliferation indices discriminated clearly between malignant melanomas and nevi, but not between common and dysplastic nevi. Nonetheless, a portion of nevi exhibited markedly elevated telomerase activity levels without proportionally increased proliferation. This was independent of discernible morphological changes. Clinicopathological correlations showed an association between high telomerase activity and early metastatic spread in melanomas, linking telomerase to tumor biology. Our results provide arguments in favor of an occasional progression from nevi to melanomas and imply that proliferation measurements in combination with telomerase assays may help to elicit early malignant transformation that is undetectable by conventional morphology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.